Upstream Bio, Inc. (UPB)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$3.70+9.14%

Close 2026-11-04 · 1-day change

Upstream Bio, Inc. (UPB) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge Upstream Bio, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for UPB yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash reserves near $341.5M through 2027	Upstream Bio has $341.5M cash to fund operations through 2027.	Intact	cash falls below $300M before end of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.76

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash reserves near $341.5M through 2027Direct metric needs a verified mapping
Reduce net losses toward breakevenPublished status: Broken
Stabilize or improve revenue from current forecastPublished status: Broken

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-91.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Upstream Bio, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a speculative clinical-development business, not an established earnings compounder, because it is loss-making and its value depends on future trial progress. The thesis is in watch mode: management is advancing key trials, but recent financial performance is below its industry cohort.

What's priced into Upstream Bio, Inc.

UPB is expensive versus peers, with a valuation premium and a wide expectations gap tied to the potential value of its clinical programs. The evidence labels that pricing as unjustified, but confidence in the valuation model is low, so the size of the gap is uncertain.

What the fundamentals likely do

Near term, results may remain uneven: the company reported an earnings beat in August after an in-line result in May, but it remains loss-making and carries elevated risk. Management says severe asthma and CRSwNP Phase 3 trials remain on track for Q1 2027, while VENTURE enrollment is complete and COPD Phase 3 preparation is planned; cash has declined, though management expects it to fund operations through 2027.

What Upstream Bio, Inc. hinges on

The multi-year thesis depends on trial progress, including the planned Q1 2027 Phase 3 starts and COPD data expected in the second half of 2027, as well as whether cash lasts as management expects. Near term, a guidance cut or further weakening in employment could add pressure, while continued strength from healthcare bellwethers could support the sector backdrop; a recent litigation filing is also a risk to watch.

Bottom line

Over the next 1 to 3 years, UPB remains a high-risk, loss-making clinical story with meaningful execution milestones and a watch status. The thesis hinges on delivering those milestones and maintaining funding through 2027. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.85	$1,925,833	7 / 5
2026-07-25	$-2.89	$1,650,710	8 / 7
2026-07-26	$-2.85	$1,925,833	7 / 5
2026-07-27	$-2.89	$1,650,710	8 / 7
2026-07-28	$-2.89	$1,650,710	8 / 7
2026-07-29	$-2.85	$1,925,833	7 / 5
2026-07-30	$-2.89	$1,650,710	8 / 7
2026-07-31	$-2.89	$1,650,710	8 / 7
2026-08-01	$-2.85	$1,925,833	7 / 5
2026-08-02	$-2.89	$1,650,710	8 / 7
2026-08-03	$-2.89	$1,650,710	8 / 7
2026-08-04	$-2.89	$1,650,710	8 / 7
2026-08-05	$-2.85	$1,925,833	7 / 5
2026-08-06	$-2.89	$1,650,710	8 / 7
2026-08-08	$-2.85	$1,925,833	7 / 5
2026-08-09	$-2.89	$1,650,710	8 / 7
2026-08-10	$-2.85	$1,925,833	7 / 5
2026-08-12	$-2.85	$1,925,833	7 / 5
2026-08-13	$-2.85	$1,925,833	7 / 5
2026-08-14	$-2.85	$1,925,833	7 / 5
2026-08-15	$-2.85	$1,925,833	7 / 5
2026-08-16	$-2.85	$1,925,833	7 / 5
2026-08-17	$-2.85	$1,925,833	7 / 5
2026-08-18	$-2.85	$1,925,833	7 / 5
2026-08-19	$-2.85	$1,925,833	7 / 5
2026-08-20	$-2.91	$1,945,667	7 / 5
2026-08-21	$-2.76	$1,634,800	7 / 5
2026-08-22	$-2.76	$1,634,800	7 / 5
2026-08-23	$-2.76	$1,634,800	7 / 5
2026-08-24	$-2.76	$1,634,800	7 / 5
2026-08-25	$-2.76	$1,634,800	7 / 5
2026-08-26	$-2.76	$1,634,800	7 / 5
2026-08-27	$-2.76	$1,634,800	7 / 5
2026-08-28	$-2.76	$1,634,800	7 / 5
2026-08-29	$-2.76	$1,634,800	7 / 5
2026-08-30	$-2.76	$1,634,800	7 / 5
2026-08-31	$-2.76	$1,634,800	7 / 5
2026-09-01	$-2.76	$1,634,800	7 / 5
2026-09-02	$-2.76	$1,634,800	7 / 5
2026-09-03	$-2.76	$1,634,800	7 / 5
2026-09-04	$-2.76	$1,634,800	7 / 5
2026-09-05	$-2.76	$1,634,800	7 / 5
2026-09-06	$-2.76	$1,634,800	7 / 5
2026-09-07	$-2.76	$1,634,800	6 / 4
2026-09-08	$-2.76	$1,634,800	6 / 4
2026-09-09	$-2.76	$1,634,763	6 / 4
2026-09-10	$-2.76	$1,634,763	6 / 4
2026-09-11	$-2.76	$1,634,763	6 / 4
2026-09-12	$-2.76	$1,634,763	6 / 4
2026-09-13	$-2.76	$1,634,763	6 / 4
2026-09-14	$-2.76	$1,634,763	6 / 4
2026-09-15	$-2.76	$1,634,763	6 / 4
2026-09-16	$-2.76	$1,634,763	6 / 4
2026-09-17	$-2.76	$1,634,763	6 / 4
2026-09-18	$-2.76	$1,634,763	6 / 4
2026-09-19	$-2.76	$1,634,763	6 / 4
2026-09-20	$-2.76	$1,634,763	6 / 4
2026-09-21	$-2.76	$1,634,763	6 / 4
2026-09-22	$-2.76	$1,634,763	6 / 4
2026-09-23	$-2.76	$1,634,763	6 / 4
2026-09-24	$-2.76	$1,634,763	6 / 4
2026-09-25	$-2.76	$1,634,763	6 / 4
2026-09-26	$-2.76	$1,634,763	6 / 4
2026-09-27	$-2.76	$1,634,763	6 / 4
2026-09-28	$-2.76	$1,634,763	6 / 4
2026-09-29	$-2.76	$1,634,763	6 / 4
2026-09-30	$-2.76	$1,634,763	6 / 4
2026-10-01	$-2.76	$1,634,763	6 / 4
2026-10-02	$-2.76	$1,634,763	6 / 4
2026-10-03	$-2.76	$1,634,763	6 / 4
2026-10-04	$-2.76	$1,634,763	6 / 4
2026-10-05	$-2.76	$1,634,763	6 / 4
2026-10-06	$-2.76	$1,634,763	6 / 4
2026-10-07	$-2.76	$1,634,763	6 / 4
2026-10-08	$-2.76	$1,634,763	6 / 4
2026-10-09	$-2.76	$1,634,763	6 / 4
2026-10-10	$-2.76	$1,634,763	6 / 4
2026-10-11	$-2.76	$1,634,763	6 / 4
2026-10-12	$-2.76	$1,634,763	6 / 4
2026-10-13	$-2.76	$1,634,763	6 / 4
2026-10-14	$-2.76	$1,634,763	6 / 4
2026-10-15	$-2.76	$1,634,763	6 / 4
2026-10-16	$-2.76	$1,634,763	6 / 4
2026-10-17	$-2.76	$1,634,763	6 / 4
2026-10-18	$-2.76	$1,634,763	6 / 4
2026-10-19	$-2.76	$1,634,763	6 / 4
2026-10-20	$-2.76	$1,634,763	6 / 4
2026-10-21	$-2.76	$1,634,763	6 / 4
2026-10-22	$-2.76	$1,634,763	6 / 4
2026-10-23	$-2.76	$1,634,763	6 / 4
2026-10-24	$-2.76	$1,634,763	6 / 4
2026-10-25	$-2.76	$1,634,763	6 / 4
2026-10-26	$-2.76	$1,634,763	6 / 4
2026-10-27	$-2.76	$1,634,763	6 / 4
2026-10-28	$-2.76	$1,634,763	6 / 4
2026-10-29	$-2.76	$1,634,763	6 / 4
2026-10-30	$-2.76	$1,634,763	6 / 4
2026-10-31	$-2.76	$1,634,763	6 / 4
2026-11-01	$-2.76	$1,634,763	6 / 4
2026-11-02	$-2.76	$1,634,763	6 / 4
2026-11-03	$-2.76	$1,634,763	6 / 4
2026-11-04	$-2.76	$1,634,763	6 / 4

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-06-01	8	2
2026-07-01	8	2
2026-08-01	7	2
2026-09-01	7	2
2026-10-01	7	2
2026-11-01	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 6–Nov 4 · 0 recorded

What could strengthen or challenge Upstream Bio, Inc.’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Upstream Bio, Inc. outlook in detail

What kind of bet this is

What's priced into Upstream Bio, Inc.

What the fundamentals likely do

What Upstream Bio, Inc. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line